vTv Therapeutics Inc. - Class A Common Stock (VTVT)
27.85
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 21st, 6:18 AM EDT
Detailed Quote
Previous Close
27.85
Open
-
Bid
27.00
Ask
32.88
Day's Range
N/A - N/A
52 Week Range
19.50 - 44.00
Volume
0
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
29,924
Chart
About vTv Therapeutics Inc. - Class A Common Stock (VTVT)
VTV Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of metabolic and neurodegenerative diseases. The company’s primary efforts are directed toward the discovery and development of small molecule drugs that address significant unmet medical needs, with a particular emphasis on conditions such as Alzheimer's disease and diabetes. VTV Therapeutics leverages its specialized research capabilities to advance innovative treatment options through rigorous clinical trials and the strategic pursuit of partnerships that support its mission to improve patient outcomes. Read More
vTv Therapeutics (NASDAQ:VTVT) used a virtual key opinion leader event to outline the continuing burden of hypoglycemia in type 1 diabetes, present patient and physician market-research findings, and review the development program for its investigational oral therapy, cadisegliatin.
Paul Sekhri, th
vTv Therapeutics reports Q2 2025 loss of $0.92 per share, missing estimates. Revenue at $0 as expected. Shares rise slightly amid focus on Phase 3 diabetes trial progress.
vTv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month timeline to accelerate key studies.
vTv Therapeutics faces a setback as the FDA places a clinical hold on its cadisegliatin program, impacting the CATT1 Phase 3 trial for type 1 diabetes.
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.27% to 38,867.91 while the NASDAQ fell 0.50% to 15,954.75. The S&P 500 also fell, dropping, 0.18% to 5,068.92.
